- Email: [email protected]
UP-03.053 Hypogonadism in Patients with Obesity
UNMODERATED POSTER SESSIONS
UP-03.052 Combination of Andropenis® Penile Extender and Oral Therapy (Peironimev ®) Versus Intralesional Verpamil for Penile Curvature Due To Peyronie’s Disease: Preliminary Results of a Randomized Phase II Trial Gontero P1, Di Marco M2, Giubilei G3, Pisano F1, Bonazzi A1, Soria F1, Fiorito C1, Oderda M1, Zitella A1, Bartoletti R4, Tizzani A1, Mondaini N4 1 Urologia 1, Università degli Studi di Torino, Turin, 2Casa di Cura Nuova Villa Claudia, Rome, 3Urologia, Ospedale di Ponte Anniccheri, Università di Firenze, Florence, 4Divisione di Urologia, Ospedale Careggi, Università di Firenze, Florence, Italy
mean value at 6 months: 32.8°) but not in arm 2 (p⫽0.07; mean baseline value: 46.7°, mean 6 months value: 37.8°). Penile length did not result significantly changed in both arms (arm 1: mean baseline value of 11.5cm, mean 6 months value of 11.7; arm 2: mean baseline value of: 10.2, mean 6 months value: 10.5). IIEF EF scores and positive responses to SEP did not show significant changes from baseline to 6 months. Conclusions: Six months treatment with Andropenis® penile extender and PeironiMEV ® resulted in significant improvement in pain and penile curvature while intraplaque Verapamil injection did not.
Introduction and Objectives: Intralesional Verapamil is a commonly used treatment option for Peyronie’s disease. Concern exists as regards its relative invasiveness and patients’ compliance. Preliminary experience suggests that penile extenders may be effective in reducing penile curvature. Aim of the current study was to compare the efficacy and tolerability of the penile extender Andropenis® with intralesional Verapamil. An oral combination of paraminobenzoate and antioxidants (PeironiMEV ®), suggested to be active on the plaque, was added to the penile stretcher arm. Materials and Methods: Peyronie’s disease patients with penile curvature were eligible. Baseline investigations included USS or caliper plaque measurements, flaccid and stretched penile measurements, degree of curvature determination using autophotograpy or in-office intracavernous injection, VAS score, IIEF and SEP questionnaires. Patients were randomized for Andropenis® to be carried for 8 ore/day ⫹ PeironiMEV ® BD for 6 months (arm 1) or intraplaque injection of Verapamil 5 mg/2 cc every 2 weeks for 6 months (arm 2). Baseline evaluations were repeated at 1, 3, 6 e 12 months. Results: Twenty-nine patients were enrolled (17 in arm 1 and 12 in arm 2), mean age 55 years (38-77), mean disease duration 8,6 months and 27 were evaluable for efficacy (1 patient each arm dropped out for inefficacy [arm 1] and pain [arm 2] respectively). VAS score significantly improved in arm 1 (p⬍0.0001; mean baseline value: 3.9, mean value at 6 months: 1.2) but not in arm 2 (p⫽0.14; mean baseline value: 1.67, mean 6 months value: 0.8). Plaque size was not significantly affected in both groups. Curvature degree was significantly reduced in arm 1 (p⫽0.004; mean baseline value of 45.9°,
UP-03.053 Hypogonadism in Patients with Obesity Rusu F1, Rusu E2,3, Radulian G2,3, Jinga M1,2, Enache G3, Jinga V2, Pricop C4,5, Cheta D2,3, Mischianu D1,2 1 Emergency Military Hospital, Bucharest, 2 University of Medicine Carol Davila, Bucharest, 3National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, 4University of Medicine, Iasi, 5Dr. IC Parhon Hospital, Iasi, Romania
S360
Introduction: Previous studies have shown a high prevalence of low levels of the endogenous sexual hormones in patients with obesity. The aim of this study was to analyze the prevalence of hypogonadism in patients with obesity. Materials and Methods: We analyzed the relationship between testosterone levels and obesity and components of metabolic syndrome in 381 patients. These patients were divided into two groups: group A: patients with obesity (O) and hypogonadism (O⫹T) and group B: patients with obesity without hypogonadism (O-T). Overweight was defined as 26-29.9 kg/m2. Obesity was defined as BMI ⱖ30 kg/m2. Male hypogonadism or androgen deficiency has been defined as a maximum level of total testosterone up to 3 ng/ml. Results: There was no significant age differences between groups (59.8⫾8.38 versus 58.31⫾7.47 years p⫽0.06). Prevalence of hypogonadism in patients with obesity was 33.5% (n⫽128). There were no significant differences between groups in terms of body weight, waist circumference, hip circumference, BMI, and blood pressure between groups (all p⬎0.05). Patients with hypogonadism had significantly higher levels of triglycerides, FPI,
HOMA-IR (all p⬍0.05) and smaller HDLcholesterol and SHBG (all p⬍0.05). There was a significant decline in testosterone concentration with increase in age and BMI. 88.3% of the diabetic patients (n⫽113) had hypogonadism (p⫽0.0001). Hypogonadism was present in 25% patients (n⫽32) with 3 components of metabolic syndrome (MetS), 43.8% (n⫽56) patients with 4 components of MetS and in 31.2% (n⫽40) patients with 5 components of MetS (p⫽0.0001). Conclusions: Hypogonadism is a common ocurrence in subjects with obesity and MetS. Males with obesity with or without diabetes have lower serum testosterone. Patients with obesity should be investigated for clinical and biochemical signs of hypogonadism and patients with hypogonadism should be investigated for signs of metabolic syndrome.
UP-03.054 Clinical Efficacy of Tape-Cutting as a Treatment for Complication in TOT Kim S, Kim S, Sung G, Kim H, Park J, Park C Dept. of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea Introduction and Objective: Compared to the previous treatments for stress incontinence, T0T is used more with its safety and less complication. However it is not free from only the complication, but also the voiding difficulty, on the contrary to the symptoms of complication. Accordingly the purpose of this study is to identify the clinical efficacy of tape cutting as a treatment for dysuria. Materials and Methods: We have researched the data of the 450 subjected patients taking TOT from 2006 to 2009 in a retrospective way. The subjects refer to the 17 patients (at the age of 65, ranging 52 to 75) without any reaction due to dysuria for more than three months, out of the patients taking tape cutting because of dysuria after TOT. After putting a patient under local anesthesia in the mucous coat area at the supine position, we made a 2cm of incision, detached and incised the TOT tape below the urethra area. We compared the several points focused on Q max, Voiding volume, RU and recurrence of incontinence before and after tape cutting. Results: Before TOT operation, the record of a patient showed Q max 17.2 (ranging 5.7⬃30.6), Voiding volume 190(ranging 38⬃386) and RU 179 (ranging 105-266). After tape cutting operation,
UROLOGY 78 (Supplement 3A), September 2011
UP-03.052 Combination of Andropenis® Penile Extender and Oral Therapy (Peironimev ®) Versus Intralesional Verpamil for Penile Curvature Due To Peyronie’s Disease: Preliminary Results of a Randomized Phase II Trial Gontero P1, Di Marco M2, Giubilei G3, Pisano F1, Bonazzi A1, Soria F1, Fiorito C1, Oderda M1, Zitella A1, Bartoletti R4, Tizzani A1, Mondaini N4 1 Urologia 1, Università degli Studi di Torino, Turin, 2Casa di Cura Nuova Villa Claudia, Rome, 3Urologia, Ospedale di Ponte Anniccheri, Università di Firenze, Florence, 4Divisione di Urologia, Ospedale Careggi, Università di Firenze, Florence, Italy
mean value at 6 months: 32.8°) but not in arm 2 (p⫽0.07; mean baseline value: 46.7°, mean 6 months value: 37.8°). Penile length did not result significantly changed in both arms (arm 1: mean baseline value of 11.5cm, mean 6 months value of 11.7; arm 2: mean baseline value of: 10.2, mean 6 months value: 10.5). IIEF EF scores and positive responses to SEP did not show significant changes from baseline to 6 months. Conclusions: Six months treatment with Andropenis® penile extender and PeironiMEV ® resulted in significant improvement in pain and penile curvature while intraplaque Verapamil injection did not.
Introduction and Objectives: Intralesional Verapamil is a commonly used treatment option for Peyronie’s disease. Concern exists as regards its relative invasiveness and patients’ compliance. Preliminary experience suggests that penile extenders may be effective in reducing penile curvature. Aim of the current study was to compare the efficacy and tolerability of the penile extender Andropenis® with intralesional Verapamil. An oral combination of paraminobenzoate and antioxidants (PeironiMEV ®), suggested to be active on the plaque, was added to the penile stretcher arm. Materials and Methods: Peyronie’s disease patients with penile curvature were eligible. Baseline investigations included USS or caliper plaque measurements, flaccid and stretched penile measurements, degree of curvature determination using autophotograpy or in-office intracavernous injection, VAS score, IIEF and SEP questionnaires. Patients were randomized for Andropenis® to be carried for 8 ore/day ⫹ PeironiMEV ® BD for 6 months (arm 1) or intraplaque injection of Verapamil 5 mg/2 cc every 2 weeks for 6 months (arm 2). Baseline evaluations were repeated at 1, 3, 6 e 12 months. Results: Twenty-nine patients were enrolled (17 in arm 1 and 12 in arm 2), mean age 55 years (38-77), mean disease duration 8,6 months and 27 were evaluable for efficacy (1 patient each arm dropped out for inefficacy [arm 1] and pain [arm 2] respectively). VAS score significantly improved in arm 1 (p⬍0.0001; mean baseline value: 3.9, mean value at 6 months: 1.2) but not in arm 2 (p⫽0.14; mean baseline value: 1.67, mean 6 months value: 0.8). Plaque size was not significantly affected in both groups. Curvature degree was significantly reduced in arm 1 (p⫽0.004; mean baseline value of 45.9°,
UP-03.053 Hypogonadism in Patients with Obesity Rusu F1, Rusu E2,3, Radulian G2,3, Jinga M1,2, Enache G3, Jinga V2, Pricop C4,5, Cheta D2,3, Mischianu D1,2 1 Emergency Military Hospital, Bucharest, 2 University of Medicine Carol Davila, Bucharest, 3National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, 4University of Medicine, Iasi, 5Dr. IC Parhon Hospital, Iasi, Romania
S360
Introduction: Previous studies have shown a high prevalence of low levels of the endogenous sexual hormones in patients with obesity. The aim of this study was to analyze the prevalence of hypogonadism in patients with obesity. Materials and Methods: We analyzed the relationship between testosterone levels and obesity and components of metabolic syndrome in 381 patients. These patients were divided into two groups: group A: patients with obesity (O) and hypogonadism (O⫹T) and group B: patients with obesity without hypogonadism (O-T). Overweight was defined as 26-29.9 kg/m2. Obesity was defined as BMI ⱖ30 kg/m2. Male hypogonadism or androgen deficiency has been defined as a maximum level of total testosterone up to 3 ng/ml. Results: There was no significant age differences between groups (59.8⫾8.38 versus 58.31⫾7.47 years p⫽0.06). Prevalence of hypogonadism in patients with obesity was 33.5% (n⫽128). There were no significant differences between groups in terms of body weight, waist circumference, hip circumference, BMI, and blood pressure between groups (all p⬎0.05). Patients with hypogonadism had significantly higher levels of triglycerides, FPI,
HOMA-IR (all p⬍0.05) and smaller HDLcholesterol and SHBG (all p⬍0.05). There was a significant decline in testosterone concentration with increase in age and BMI. 88.3% of the diabetic patients (n⫽113) had hypogonadism (p⫽0.0001). Hypogonadism was present in 25% patients (n⫽32) with 3 components of metabolic syndrome (MetS), 43.8% (n⫽56) patients with 4 components of MetS and in 31.2% (n⫽40) patients with 5 components of MetS (p⫽0.0001). Conclusions: Hypogonadism is a common ocurrence in subjects with obesity and MetS. Males with obesity with or without diabetes have lower serum testosterone. Patients with obesity should be investigated for clinical and biochemical signs of hypogonadism and patients with hypogonadism should be investigated for signs of metabolic syndrome.
UP-03.054 Clinical Efficacy of Tape-Cutting as a Treatment for Complication in TOT Kim S, Kim S, Sung G, Kim H, Park J, Park C Dept. of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea Introduction and Objective: Compared to the previous treatments for stress incontinence, T0T is used more with its safety and less complication. However it is not free from only the complication, but also the voiding difficulty, on the contrary to the symptoms of complication. Accordingly the purpose of this study is to identify the clinical efficacy of tape cutting as a treatment for dysuria. Materials and Methods: We have researched the data of the 450 subjected patients taking TOT from 2006 to 2009 in a retrospective way. The subjects refer to the 17 patients (at the age of 65, ranging 52 to 75) without any reaction due to dysuria for more than three months, out of the patients taking tape cutting because of dysuria after TOT. After putting a patient under local anesthesia in the mucous coat area at the supine position, we made a 2cm of incision, detached and incised the TOT tape below the urethra area. We compared the several points focused on Q max, Voiding volume, RU and recurrence of incontinence before and after tape cutting. Results: Before TOT operation, the record of a patient showed Q max 17.2 (ranging 5.7⬃30.6), Voiding volume 190(ranging 38⬃386) and RU 179 (ranging 105-266). After tape cutting operation,
UROLOGY 78 (Supplement 3A), September 2011